Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteopor...(higher predictive valueand greater speci...),Health

About Bionovo's SERM Platform

Bionovo is discovering and developing a new generation of novel selective estrogen modulators. The selectivity is based on receptor subtype regulation, agonist, antagonist effect, selective gene activation and repression and specific recruitment of co-regulatory proteins. Selective estrogen receptor modulators can be useful for many indications in women's health such as breast and uterine cancer, osteoporosis, menopausal symptoms, vaginal atrophy, endometriosis, uterine fibroids and other disorders. This platform provides Bionovo the molecular, pharmacological and toxicological insights needed for drugs of the future.

About Bionovo

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, which are markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects,"
'/>"/>